Ampio's Phase I study for inhaled Ampion advances to completing enrollment of COVID-19 patients

Ampio's Phase I study for inhaled Ampion advances to completing enrollment of COVID-19 patients

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced its AP-014 Phase I inhaled Ampion clinical study in COVID-19 patients is proceeding to full open enrollment following... Read More

Friday December 4, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Michael Macaluso, COVID-19, Inhaled Ampion

Ampio's Phase I study for Inhaled Ampion advances to 2nd group of COVID-19 patients with lung distress

Ampio's Phase I study for Inhaled Ampion advances to 2nd group of COVID-19 patients with lung distress

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced the second group in the Phase I inhaled Ampionclinical study is being treated following clearance by the Safety Monitoring... Read More

Wednesday November 11, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Inhaled Ampion, Michael Macaluso, COVID-19